ArticleAtherosclerosis2014
Increased atherosclerosis in mice with increased vascular biglycan content.
Article in Atherosclerosis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Development and Validation of a Flow-Dependent Endothelialized 3D Model of Intracranial Atherosclerotic Disease.Translational stroke research · 2025Article
- Vascular Extracellular Matrix in Atherosclerosis.International journal of molecular sciences · 2024Review
- Review
- Article
- Article
- The Shear Stress-Regulated Expression of Glypican-4 in Endothelial Dysfunction In Vitro and Its Clinical Significance in Atherosclerosis.International journal of molecular sciences · 2023Article
- Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis.Handbook of experimental pharmacology · 2022Review
- Biglycan: an emerging small leucine-rich proteoglycan (SLRP) marker and its clinicopathological significance.Molecular and cellular biochemistry · 2021Review
- Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans.Journal of translational medicine · 2021Article
- ADAMTS proteases in cardiovascular physiology and disease.Open biology · 2020Review
- Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation.Frontiers in immunology · 2020Review
- Vascular smooth muscle cells in atherosclerosis.Nature reviews. Cardiology · 2019Review
- Role of serum amyloid A in atherosclerosis.Current opinion in lipidology · 2019Review
- A role for proteoglycans in vascular disease.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Serum Amyloid A Is an Exchangeable Apolipoprotein.Arteriosclerosis, thrombosis, and vascular biology · 2018Article
- Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice.Atherosclerosis · 2018Article
- The arterial microenvironment: the where and why of atherosclerosis.The Biochemical journal · 2016Review
- Toll-like Receptors in the Vascular System: Sensing the Dangers Within.Pharmacological reviews · 2016Review
- Serglycin protects against high fat diet-induced increase in serum LDL in mice.Glycoconjugate journal · 2015Article
- The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis.Journal of internal medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe response to retention hypothesis of atherogenesis proposes that atherosclerosis is initiated via the retention of atherogenic lipoproteins by vascular proteoglycans. Co-localization studies suggest that of all the vascular proteoglycans, biglycan is the one most closely co-localized with LDL. The goal of this study was to determine if over-expression of biglycan in hyperlipidemic mice would increase atherosclerosis development.
methodsTransgenic mice were developed by expressing biglycan under control of the smooth muscle actin promoter, and were crossed to the LDL receptor deficient (C57BL/6 background) atherosclerotic mouse model. Biglycan transgenic and non-transgenic control mice were fed an atherogenic Western diet for 4-12 weeks.
resultsLDL receptor deficient mice overexpressing biglycan under control of the smooth muscle alpha actin promoter had increased atherosclerosis development that correlated with vascular biglycan content.
conclusionIncreased vascular biglycan content predisposes to increased lipid retention and increased atherosclerosis development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.